LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health infrastructure and AI-supported medical solutions for Latin America, announced that development of its mobile healthcare application has entered its final stage. The company is currently completing testing, optimization, and deployment preparation ahead of planned availability through the Apple App Store and Google Play. Management expects the application to be submitted for distribution and, subject to platform review, become available in the coming weeks.
The application is being developed as a primary mobile access point to the LataMed AI digital healthcare ecosystem, providing users with a convenient interface to access supported healthcare services and digital tools. Once publicly available, it is expected to serve as a scalable mobile foundation for introducing additional functionality over time. Potential features may include patient-facing tools, healthcare-provider interaction, digital communications, medical and wellness information, and healthcare-service coordination.
Mobile accessibility is particularly important to LataMed AI's strategy in Latin America, where smartphones are a primary means of accessing digital services. By making the platform available through both major app stores, the company aims to provide users with a direct and accessible way to interact with its developing healthcare ecosystem. The app is also expected to support the company's longer-term strategy of connecting patients, healthcare professionals, pharmacies, insurers, payment providers, wellness organizations, and other participants within a more integrated digital healthcare environment.
LataMed AI continues to develop AI-supported technologies, including CardioAI, PulmoAI, and NeuroAI, as part of its broader strategy. The mobile infrastructure is intended to provide an additional pathway for users and healthcare professionals to interact with supported components of the ecosystem, subject to continued development and regulatory requirements.
“Our mobile application is now moving from development toward deployment, and we believe we are approaching an important milestone for LataMed AI,” said Dr. Kevin Rodan Levy, CEO. “Our team is completing the final stages of testing and preparation, and we currently expect the application to become available through the Apple App Store and Google Play in the coming weeks, subject to the applicable platform review processes.”
Dr. Levy added, “Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building. Our objective is to create a platform that is practical, accessible, and capable of expanding as we continue introducing additional healthcare services and AI-supported tools.”
The company believes the mobile release represents a step in moving its technology from development into user-facing digital healthcare infrastructure. Following the initial release, LataMed AI intends to evaluate additional functionality, platform integrations, and user-facing tools for future versions. The company expects to provide updates on submission, availability, and functionality as milestones are completed.
For additional information, visit https://latamed.ai or review the company's filings with the SEC at www.sec.gov.
